<DOC>
	<DOCNO>NCT01757262</DOCNO>
	<brief_summary>Study Vietnamese Patients Coronary Heart Disease investigate safety P2Y12 Receptor Inhibition Effects Ticagrelor Clopidogrel</brief_summary>
	<brief_title>A Clinical Study Safety P2Y12 Receptor Inhibition Effects Ticagrelor Clopidogrel Vietnamese Patient</brief_title>
	<detailed_description>Safety P2Y12 Receptor Inhibition Effects Ticagrelor Clopidogrel Vietnamese Patients Coronary Heart Disease : A Randomized , Open Label , Crossover Study</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Male female Vietnamese patient ( confirm Principal Investigator ) age &gt; 18 year suitable vein cannulation repeat venipuncture stable coronary heart disease Stable use aspirin 75 100 mg daily least precede 2 week continue throughout study period Have body mass index ( BMI ) 18 30 kg/m2 inclusive Women must negative urine pregnancy test Visit 1 History clinically significant disease disorder , opinion investigator , may either put patient risk participation study , influence result patient 's ability participate study Unstable angina clinically significant illness , medical/surgical procedure trauma within 4 week first administration IP Patients acute coronary syndrome stent place within 12 month screen Planned arterial revascularization Current use ADP receptor blocker ( eg , clopidogrel , ticlopidine , prasugrel ) , dipyridamole cilostazol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Coronary Heart Disease</keyword>
</DOC>